Finerenone in patients with type 2 diabetes mellitus and diabetic kidney disease: A retrospective clinical study
Authors/Creators
- 1. Department of Nephrology, Medical University of Plovdiv, St George University Hospital, Plovdiv, Bulgaria
- 2. Section of Cardiology, First Department of Internal Diseases, Medical University of Plovdiv, Plovdiv, Bulgaria|Clinic of Cardiology, St. George University Hospital, Plovdiv, Bulgaria
- 3. Faculty of Medicine, Medical University of Plovdiv, Plovdiv, Bulgaria
- 4. Section of Cardiology, First Department of Internal Diseases, Medical University of Plovdiv, Plovdiv, Bulgaria|Research Institute at Medical University of Plovdiv, Medical University of Plovdiv, Plovdiv, Bulgaria|Department of Nephrology, Medical University of Plovdiv, St George University Hospital, Plovdiv, Bulgaria
- 5. Deparment of Healthcare Management, Faculty of Public Health, Medical University of Plovdiv, Plovdiv, Bulgaria
Description
Background: Diabetic kidney disease (DKD) is a leading cause of chronic kidney disease progression and increased cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). Despite optimized standard therapy, substantial residual renal risk persists. Finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, has demonstrated cardiorenal benefits in large randomized clinical trials.
Materials and methods: This single-center retrospective observational study included 82 adult patients with T2DM and DKD treated with finerenone as add-on therapy to standard care. Renal parameters—including serum creatinine, estimated glomerular filtration rate (eGFR), microalbuminuria, urine albumin-to-creatinine ratio (UACR), and serum potassium—were evaluated at baseline and after 6–12 months of therapy. Data are presented as mean ± SD. A paired student's t-test or Wilcoxon test was used as appropriate, with p < 0.05 considered statistically significant.
Results: Mean age was 68.1 ± 10.2 years, and 54.9% of patients were women. After therapy, serum creatinine increased modestly (Δ +2.9%, p < 0.001), while eGFR declined slightly (Δ −4.4%, p < 0.001). Significant reductions were observed in microalbuminuria (Δ −16.6%, p < 0.001) and UACR (Δ −21.0%, p < 0.001). Serum potassium increased (Δ +9.5%, p < 0.001), remaining within clinically acceptable limits. Subgroup analysis demonstrated significant UACR reduction across different albuminuria categories.
Conclusion: In patients with T2DM and DKD, finerenone therapy was associated with significant reductions in albuminuria and modest changes in renal function parameters during routine follow-up. These findings are consistent with data from randomized clinical trials and support the role of finerenone as part of a comprehensive therapeutic approach in albuminuric DKD.
Files
PHAR_article_188831.pdf
Additional details
References
- Agarwal R, Filippatos G, Pitt B, Anker SD, Rossing P, Joseph A, Kolkhof P, Nowack C, Gebel M, Ruilope LM, Bakris GL (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: FIDELITY pooled analysis of FIDELIO-DKD and FIGARO-DKD. European Heart Journal 43(6): 474–487. https://doi.org/10.1093/eurheartj/ehab777
- Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: Challenges, progress, and possibilities. Clinical Journal of the American Society of Nephrology 12(12): 2032–2045. https://doi.org/10.2215/CJN.11491116
- American Diabetes Association (2024) Chronic kidney disease and risk management: Standards of care in diabetes-2024. Diabetes Care 47(Suppl 1): S219–S226. https://doi.org/10.2337/dc24-S011
- Bakris GL, Agarwal R, Anker SD, Pitt B, Ruilope LM, Rossing P, Kolkhof P, Nowack C, Schloemer P, Joseph A, Filippatos G (2020) Effect of finerenone on kidney failure and cardiovascular outcomes in chronic kidney disease and type 2 diabetes. New England Journal of Medicine 383(23): 2219–2229. https://doi.org/10.1056/NEJMoa2025845
- European Medicines Agency (2024a) Kerendia (finerenone): EPAR – summary of product characteristics. https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia
- European Medicines Agency (2024b) Kerendia (finerenone): Product information. https://www.ema.europa.eu/en/documents/product-information/kerendia-epar-product-information_en.pdf
- Georgianos PI, Agarwal R (2023) Mineralocorticoid receptor antagonism in diabetic kidney disease: Mechanisms and clinical implications. Clinical Kidney Journal 16(5): 797–807. https://doi.org/10.1093/ckj/sfad087
- Kidney Disease: Improving Global Outcomes [KDIGO] (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. https://kdigo.org/wp-content/uploads/2022/10/KDIGO-2022-Clinical-Practice-Guideline-for-Diabetes-Management-in-CKD.pdf
- Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P, Joseph A, Kolkhof P, Nowack C, Schloemer P, Ruilope LM (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. New England Journal of Medicine 385(24): 2252–2263. https://doi.org/10.1056/NEJMoa2110956